Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by investment analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday.
Several other research firms have also recently weighed in on MIRN. Zacks Investment Research raised Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Thursday, July 14th. Citigroup Inc. cut Mirna Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $7.00 to $4.50 in a research report on Tuesday, August 16th. Leerink Swann cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $10.00 to $4.00 in a research report on Monday, August 15th. HC Wainwright began coverage on Mirna Therapeutics in a research report on Monday, September 12th. They set a “buy” rating and a $6.00 price objective for the company. Finally, Cantor Fitzgerald cut Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Mirna Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.96.
Mirna Therapeutics (NASDAQ:MIRN) opened at 1.96 on Wednesday. Mirna Therapeutics has a 12 month low of $1.82 and a 12 month high of $11.01. The company’s market capitalization is $40.84 million. The firm has a 50-day moving average price of $3.05 and a 200 day moving average price of $4.08.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.